Teknova to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022
Alpha Teknova (Nasdaq: TKNO) has announced it will report its financial results for the fourth quarter and full year 2021 on March 15, 2022, after market close. A webcast and conference call will follow at 4:30 p.m. ET. This session will provide insights into the company's performance, focusing on critical reagents for drug therapies and diagnostics. The company is known for its agility in delivering custom products for bioprocessing and molecular diagnostics.
- Expected financial results announcement may provide insights into company performance.
- Focus on critical reagents positions Teknova well in the biotech market.
- None.
HOLLISTER, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year 2021 on Tuesday, March 15, 2022, following the close of market.
Teknova will host a webcast and conference call on Tuesday, March 15, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/6tqmpjbi. The conference call can also be accessed by dialing +1 877-312-1451 for domestic callers and +1 470-495-9521 for international callers. The conference ID number is 5787239. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale across all stages of development, including commercialization.
FAQ
When will Alpha Teknova report its financial results?
What is the significance of the financial results announcement for TKNO?
How can I access the Teknova conference call?
What products does Alpha Teknova provide?
